Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
SPHDF'
s EV-to-OCF Range Over the Past 10 Years
Min: -16.65 Med: -2.85 Max: 64.31
Current: -7.52
During the past 13 years, the highest EV-to-OCF of Santhera Pharmaceuticals Holding AG was 64.31. The lowest was -16.65. And the median was -2.85.
SPHDF's EV-to-OCF is ranked better than 63.82% of 1407
companies
in the Biotechnology industry
Industry Median: -3.45
vs SPHDF: -7.52
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Santhera Pharmaceuticals Holding AG (OTCPK:SPHDF) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Santhera Pharmaceuticals Holding AG's PE Ratio (TTM) for today is calculated as:
Santhera Pharmaceuticals Holding AG's share price for today is $23.25.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Santhera Pharmaceuticals Holding AG's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $-4.667.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Santhera Pharmaceuticals Holding AG EV-to-OCF Related Terms
Santhera Pharmaceuticals Holding AG EV-to-OCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG EV-to-OCF Chart
For the Biotechnology subindustry, Santhera Pharmaceuticals Holding AG's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Santhera Pharmaceuticals Holding AG EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Santhera Pharmaceuticals Holding AG's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Santhera Pharmaceuticals Holding AG's EV-to-OCF falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Santhera Pharmaceuticals Holding AG (SPHDF) has a EV-to-OCF of -7.46 as of Aug. 09, 2026. According to the industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #509 out of 1407 companies in the Biotechnology industry, placing it in the top 36.2%.
Is Santhera Pharmaceuticals Holding AG's EV-to-OCF too high?
Santhera Pharmaceuticals Holding AG's current EV-to-OCF is -7.46. Based on the distribution chart, Santhera Pharmaceuticals Holding AG ranks #509 out of 1407 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Santhera Pharmaceuticals Holding AG has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Santhera Pharmaceuticals Holding AG's EV-to-OCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Santhera Pharmaceuticals Holding AG ranks #509 out of 1407 companies for EV-to-OCF. This puts Santhera Pharmaceuticals Holding AG in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Santhera Pharmaceuticals Holding AG's current EV-to-OCF is -7.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Santhera Pharmaceuticals Holding AG stock overvalued right now?
Santhera Pharmaceuticals Holding AG (SPHDF) has a current EV-to-OCF of -7.46. The stock's GF Value™ is $34.74, compared to a current price of $23.25 — trading 33.1% below its estimated fair value. The current EV-to-OCF is -7.46. Santhera Pharmaceuticals Holding AG's overall GF Score™ is 34/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Santhera Pharmaceuticals Holding AG (SPHDF), the current EV-to-OCF is -7.46 as of Aug. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Santhera Pharmaceuticals Holding AG (SPHDF) Overvalued in 2026?
Based on GuruFocus' analysis, Santhera Pharmaceuticals Holding AG stock appears to be undervalued.
The current stock price of $23.25 is trading 33.1% below its estimated GF Value™ of $34.74.
Key valuation signals for SPHDF:
EV-to-OCF: -7.46
GF Value™: $34.74 vs. price of $23.25 (33.1% below fair value)
No single metric tells the full story. See the SPHDF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Santhera Pharmaceuticals Holding AG is a Swiss specialty pharmaceutical company committed to developing and commercializing medicines to meet the needs of patients living with rare and other diseases with high unmet medical needs. It is focused on the development of treatments for pulmonary and neuromuscular diseases that currently lack treatment options. The company is currently engaged in the rollout of its AGAMREE (vamorolone) medicine for the treatment of Duchenne muscular dystrophy (DMD) globally. Santhera has one operating segment, namely the development and commercialization of products for the treatment of neuromuscular diseases. Geographically, the company generates maximum revenue from Europe, and the rest from Asia and North America.
34GF Score
Get the complete analysis for SPHDF
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SPHDF has been successfully added to your 
